Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA) (MarrowCHAMP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02863926
Recruitment Status : Completed
First Posted : August 11, 2016
Last Update Posted : February 11, 2019
Sponsor:
Collaborator:
Zimmer Biomet
Information provided by (Responsible Party):
Michael Murphy, Indiana University School of Medicine

Brief Summary:
Patients scheduled for major extremity lower amputation to receive bone marrow cells (cBMA) injected IM in the leg proximal to the amputation in the index limb to prevent ischemic wound complications after surgery.

Condition or disease Intervention/treatment Phase
Peripheral Artery Disease Vascular Disease Critical Limb Ischemia Biological: Injection of cBMA aspirate into the index leg Phase 1

Detailed Description:

Patients scheduled for amputation will receive bone marrow cells concentrated via the MarrowStim device (cBMA) injected IM at 25 sites in the leg proximal to the amputation in the index limb to prevent ischemic wound complications after surgery. cBMA will be injected into the anterior tibialis muscle below the point of amputation in an area approximately 3cm^2 x 2cm^2 for analytical purposes. Patients will be scheduled for amputation at Days 7, 14, or 21 post injection. Safety will be evaluated by review of treatment related adverse events (AE) during the 52-week follow-up period. The investigator will compare rates of wound complications and amputation revisions to historical controls at the institution to assess trends in therapeutic efficacy.

Patients will undergo amputation and injection sites will be harvested at that time. Immunohistochemical staining (IHC) will determine capillary density and local host immune responses. Angiogenic and inflammatory cytokines will be quantified using a multiplex array system and quantitative polymerase chain reaction (PCR).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Concentrated Autologous Concentrated Bone Marrow Aspirate (cBMA) in Preventing Wound Complications in Below Knee Amputation (BKA) (The MarrowCHAMP Study)
Actual Study Start Date : January 2017
Actual Primary Completion Date : December 19, 2017
Actual Study Completion Date : July 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Day 7
BKA performed at 7 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
Biological: Injection of cBMA aspirate into the index leg
Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
Other Names:
  • concentrated bone marrow
  • cBMA

Experimental: Day 14
BKA performed at 14 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
Biological: Injection of cBMA aspirate into the index leg
Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
Other Names:
  • concentrated bone marrow
  • cBMA

Experimental: Day 21
BKA performed at 21 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
Biological: Injection of cBMA aspirate into the index leg
Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
Other Names:
  • concentrated bone marrow
  • cBMA




Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events occurring during the enrollment period as assessed by the Investigator using the CTCAE 4.0 scale. [ Time Frame: Primary follow up in a 12 month period ]
    Safety will be evaluated by review of treatment related AEs during the 12-month follow-up period. The study will be terminated in the event of a Grade 4-5 unexpected event based on the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Treatment-related AEs will be categorized overlapping systems and severities. Three categories of systems are cardiovascular, respiratory, or infectious. Two categories of severity will be serious adverse (SAE) and major adverse cardiac events (MACE). Binomial confidence Intervals at the 95% confidence level and p-values for these 3 groups will be calculated. Since previous trials have not reported AEs with cBMA treatment, confidence intervals will be generated by the method of the Wilson Score Interval.


Secondary Outcome Measures :
  1. Time period of retention of allogeneic MSCs in harvested human skeletal muscle tissue post-MSC implantation as measured by immunohistochemical staining and number of MSCs per section of skeletal muscle at each time point . [ Time Frame: Primary follow up in a 12 month period ]
    Sections of skeletal muscle collected from each injection site will be stained with specific antibodies for MSC specific markers and the number of MSCs will be counted in each field under a microscope.

  2. The role of MSCs injected in human skeletal muscle at the time of below knee amputation as evidenced by recruitment of proangiogenic hematopoietic cells into sites of ischemia. [ Time Frame: Primary follow up in a 12 month period ]
    Continuous confidence intervals at the 95% level will be constructed to explore differences among the time-tiered administration of MSC for the quantity of capillary density in muscle fibers, examine changes in morphology, and the recruitment of HIF-1a/SDF-1/CXCR4 to ischemic muscle.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be ≥ 40 and ≤90 years of age.
  2. Patients requiring below knee amputation, as determined by an independent vascular specialist.
  3. If ulceration or gangrene present, it is distal to malleoli (to allow adequate length of ATM for 4 injections 4 cm. apart)
  4. BKA can safely be performed up to 30 days after screening, as determined by an independent vascular or orthopedic surgeon. This information will be documented in subjects' case report forms (CRFs).
  5. Females of childbearing potential must be willing to use one form of birth control for the duration of the study. Female participants must undergo a blood or urine pregnancy test at screening.

Exclusion Criteria:

  1. Patients who are pregnant, planning to become pregnant in the next 12 months, or lactating.
  2. Significant hepatic dysfunction (ALT or AST greater than 2 times normal).
  3. CHF hospitalization within the last 1 month prior to enrollment.*
  4. Acute coronary syndrome (ACS) in the last 1 month prior to enrollment.*
  5. HIV positive, or active, untreated HCV.
  6. History of cancer within the last 5 years, except basal cell skin carcinoma
  7. Any bleeding diathesis defined as an INR ≥ 2.0 (off anticoagulation therapy) or history of platelet count less than 70,000 or hemophilia.
  8. Inability to provide written informed consent due to cognitive or language barriers (interpreter permitted).
  9. Concurrent enrollment in another clinical investigative trial.
  10. Any condition requiring immunosuppressant medications (e.g., for treatment of organ transplants, psoriasis, Crohn's disease, alopecia areata).
  11. Presence of any clinical condition that in the opinion of the PI or the sponsor makes the patient not suitable to participate in the trial.

    • As defined by the standard definitions of CHF and ACS by the American Heart Association.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02863926


Locations
Layout table for location information
United States, Indiana
Indiana University School of Medicine
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Michael Murphy
Zimmer Biomet
Investigators
Layout table for investigator information
Principal Investigator: Michael P Murphy, MD Indiana University

Publications:

Layout table for additonal information
Responsible Party: Michael Murphy, Principal Investigator, MD, Indiana University School of Medicine
ClinicalTrials.gov Identifier: NCT02863926     History of Changes
Other Study ID Numbers: 1511774456
First Posted: August 11, 2016    Key Record Dates
Last Update Posted: February 11, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified data will be shared with investigators at the Indiana University School of Medicine as well as at other collaborating institutions.

Keywords provided by Michael Murphy, Indiana University School of Medicine:
vascular disease
peripheral artery disease
stem cells
BKA
amputation
MarrowStim
below knee amputation
wound complication
critical limb ischemia
AKA
bone marrow

Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemia
Vascular Diseases
Peripheral Arterial Disease
Pathologic Processes
Cardiovascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Peripheral Vascular Diseases